Related Experiment Videos
[Sulmazole: a new positive inotropic agent].
Annales De Cardiologie Et D'Angeiologie
|May 1, 1984
Summary
Sulmazol, a positive inotropic agent, significantly improved cardiac index and reduced pulmonary capillary pressure in heart failure patients over 24 hours. This new vasodilator shows promise for treating acute and chronic heart failure.
Area of Science:
- Cardiology
- Pharmacology
Context:
- Heart failure is a complex cardiovascular condition characterized by impaired cardiac function.
- Hemodynamic monitoring is crucial for assessing the severity and guiding treatment of heart failure.
Purpose:
- To evaluate the hemodynamic effects of Sulmazol (AR-L 115 BS), a novel positive inotropic agent with vasodilator properties, in patients with heart failure.
- To assess the efficacy of a 24-hour intravenous infusion of Sulmazol in patients with chronic decompensation and acute myocardial infarction-induced heart failure.
Summary:
- A 24-hour intravenous infusion of Sulmazol was administered to 17 heart failure patients meeting specific hemodynamic criteria.
- Significant improvements were observed, including increased cardiac index (40-45%) and decreased pulmonary capillary pressure (30-32%) and right atrial pressure (31-51%).
- Total systemic resistance decreased (32-34%) without significant changes in systolic blood pressure; heart rate increased only in the acute myocardial infarction group.
Impact:
- Sulmazol demonstrated significant and sustained beneficial hemodynamic effects in patients with acute and chronic heart failure.
- The findings suggest Sulmazol is a potentially effective treatment for heart failure, though long-term tolerance requires further investigation.
- This study provides valuable data on the acute hemodynamic profile of Sulmazol in a heart failure population.